Pfizer Japan Inc. (‘Pfizer’) and Takeda Pharmaceutical Company Limited (‘Takeda’), today announced the termination of co-promotion for the rheumatoid arthritis/juvenile idiopathic arthritis treatment ‘Enbrel®‘ (generic name: etanercept (rDNA); hereinafter, ‘Enbrel’), at the end of November 2019. Pfizer is the Marketing Authorization Holder (‘MAH’) of Enbrel.
In March 2005, Enbrel 25 mg for subcutaneous injection was launched in Japan, and Pfizer and Takeda have co-promoted it under a co-promotion agreement. Enbrel was launched in syringe-type in June 2008 and in pen-type in June 2013, offering various doses and dosage types to meet the needs of patients with rheumatoid arthritis and juvenile idiopathic arthritis, as well as those of medical personnel. Takeda and Pfizer have to date been working together to promote the proper use of the drug.
As a result of discussions between the two companies prompted by changes in the business environment, the co-promotion will be terminated by the end of November 2019. From December 2019, Enbrel will be promoted solely by Pfizer, the MAH of the drug. However, Takeda will be responsible for distribution until the end of March 2020. What happens after that is now under discussion.
Moving forward, Pfizer and Takeda will complete the smooth transfer of promotion of Enbrel to Pfizer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.